Dataset from Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

This study was designed to enable all subjects who received placebo in the HPV-039 study
(NCT00779766), to also receive GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine,
Adsorbed. Safety data in terms of serious adverse events (SAEs), any adverse events
(AEs)/SAEs leading to premature discontinuation of the study, potential immune mediated
diseases (pIMDs) and pregnancies (and their outcomes) were collected during the study period.

In addition, this study assessed the long term protective effect of the vaccine, in an
exploratory manner, in terms of rates of HPV-related (vaccine type) incident cervical
infection up to approximately 10 years after vaccination in subjects who participated in
HPV-039 study (NCT00779766).